 Charles Neff
Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 21 | 2024 | 2720 | 1.740 |
Why?
| | HIV-1 | 11 | 2018 | 836 | 1.380 |
Why?
| | Aptamers, Nucleotide | 4 | 2023 | 77 | 1.320 |
Why?
| | Anti-Inflammatory Agents | 4 | 2022 | 480 | 1.090 |
Why?
| | CD4-Positive T-Lymphocytes | 10 | 2021 | 1056 | 0.930 |
Why?
| | Herpesvirus 1, Human | 1 | 2023 | 86 | 0.800 |
Why?
| | Cyclohexanes | 2 | 2011 | 22 | 0.730 |
Why?
| | Macrophages, Alveolar | 2 | 2020 | 389 | 0.670 |
Why?
| | Microbiota | 6 | 2024 | 730 | 0.660 |
Why?
| | Triazoles | 2 | 2011 | 152 | 0.650 |
Why?
| | Interleukin-10 | 2 | 2022 | 304 | 0.620 |
Why?
| | Inflammation | 7 | 2024 | 2736 | 0.620 |
Why?
| | Polysaccharides, Bacterial | 2 | 2022 | 67 | 0.560 |
Why?
| | Vagina | 4 | 2012 | 175 | 0.560 |
Why?
| | Viral Load | 4 | 2018 | 448 | 0.540 |
Why?
| | Feces | 3 | 2021 | 440 | 0.540 |
Why?
| | RNA, Small Interfering | 4 | 2012 | 587 | 0.530 |
Why?
| | Gastrointestinal Microbiome | 6 | 2024 | 641 | 0.530 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2021 | 857 | 0.520 |
Why?
| | Homosexuality, Male | 4 | 2022 | 175 | 0.480 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2021 | 375 | 0.460 |
Why?
| | Bacteria | 3 | 2022 | 820 | 0.460 |
Why?
| | Immune Tolerance | 1 | 2016 | 355 | 0.440 |
Why?
| | B7-H1 Antigen | 4 | 2019 | 196 | 0.380 |
Why?
| | Anti-HIV Agents | 4 | 2016 | 754 | 0.370 |
Why?
| | CCR5 Receptor Antagonists | 1 | 2011 | 6 | 0.370 |
Why?
| | Programmed Cell Death 1 Receptor | 5 | 2019 | 232 | 0.360 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2011 | 135 | 0.360 |
Why?
| | Anti-Infective Agents, Local | 1 | 2011 | 42 | 0.360 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2010 | 8 | 0.360 |
Why?
| | Pyrrolidinones | 1 | 2010 | 29 | 0.350 |
Why?
| | Leukocytes, Mononuclear | 5 | 2022 | 545 | 0.350 |
Why?
| | Sexual and Gender Minorities | 3 | 2022 | 194 | 0.320 |
Why?
| | Cytokines | 6 | 2021 | 2017 | 0.320 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2021 | 149 | 0.300 |
Why?
| | Lung Diseases | 1 | 2015 | 742 | 0.300 |
Why?
| | Vitiligo | 2 | 2019 | 41 | 0.280 |
Why?
| | Disease Models, Animal | 7 | 2024 | 4063 | 0.260 |
Why?
| | Mice | 17 | 2024 | 16937 | 0.250 |
Why?
| | Animals | 21 | 2024 | 35360 | 0.240 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 644 | 0.240 |
Why?
| | Flow Cytometry | 6 | 2015 | 1156 | 0.240 |
Why?
| | Herpesvirus 3, Human | 2 | 2019 | 331 | 0.220 |
Why?
| | Receptors, CCR5 | 2 | 2021 | 57 | 0.220 |
Why?
| | Herpesvirus 2, Human | 1 | 2023 | 28 | 0.220 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 426 | 0.210 |
Why?
| | Guinea Pigs | 1 | 2023 | 157 | 0.210 |
Why?
| | Viral Envelope Proteins | 1 | 2023 | 81 | 0.210 |
Why?
| | Interleukin-1 | 2 | 2019 | 958 | 0.200 |
Why?
| | Smokers | 2 | 2020 | 138 | 0.200 |
Why?
| | Lymphocyte Activation | 2 | 2018 | 1106 | 0.200 |
Why?
| | Antibodies, Viral | 2 | 2023 | 601 | 0.190 |
Why?
| | Humans | 34 | 2024 | 129622 | 0.190 |
Why?
| | Immunity, Innate | 2 | 2019 | 804 | 0.180 |
Why?
| | Firmicutes | 1 | 2021 | 18 | 0.180 |
Why?
| | Up-Regulation | 3 | 2019 | 840 | 0.180 |
Why?
| | Melanoma, Experimental | 1 | 2021 | 108 | 0.170 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 7 | 0.170 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2021 | 64 | 0.170 |
Why?
| | Haplotypes | 2 | 2019 | 475 | 0.160 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.160 |
Why?
| | Immunophenotyping | 1 | 2020 | 311 | 0.160 |
Why?
| | Homeodomain Proteins | 3 | 2012 | 495 | 0.160 |
Why?
| | Hexosaminidases | 1 | 2019 | 18 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1198 | 0.160 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2019 | 525 | 0.160 |
Why?
| | HLA-DQ Antigens | 2 | 2019 | 179 | 0.160 |
Why?
| | Genes, MHC Class II | 1 | 2019 | 73 | 0.150 |
Why?
| | Female | 14 | 2023 | 68770 | 0.150 |
Why?
| | Dysbiosis | 2 | 2021 | 169 | 0.150 |
Why?
| | Disease | 1 | 2019 | 95 | 0.150 |
Why?
| | Lung | 4 | 2022 | 3931 | 0.150 |
Why?
| | Mice, Transgenic | 3 | 2019 | 2119 | 0.150 |
Why?
| | Immune System | 1 | 2019 | 175 | 0.150 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 118 | 0.140 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 424 | 0.140 |
Why?
| | HIV | 1 | 2019 | 226 | 0.140 |
Why?
| | Principal Component Analysis | 1 | 2018 | 189 | 0.140 |
Why?
| | Toll-Like Receptors | 1 | 2018 | 179 | 0.140 |
Why?
| | Nitriles | 1 | 2018 | 172 | 0.140 |
Why?
| | HIV-2 | 1 | 2016 | 18 | 0.140 |
Why?
| | Dideoxynucleosides | 1 | 2016 | 20 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2016 | 31 | 0.130 |
Why?
| | Lamivudine | 1 | 2016 | 61 | 0.130 |
Why?
| | Inflammasomes | 1 | 2018 | 126 | 0.130 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 590 | 0.120 |
Why?
| | Retroviridae Infections | 1 | 2015 | 46 | 0.120 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2016 | 99 | 0.120 |
Why?
| | Immune Evasion | 1 | 2015 | 56 | 0.120 |
Why?
| | HIV Antigens | 1 | 2015 | 17 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2016 | 200 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 220 | 0.120 |
Why?
| | Inflammation Mediators | 1 | 2018 | 505 | 0.120 |
Why?
| | HLA-DR Antigens | 1 | 2016 | 224 | 0.120 |
Why?
| | Interleukin Receptor Common gamma Subunit | 2 | 2011 | 14 | 0.120 |
Why?
| | Software | 1 | 2019 | 608 | 0.110 |
Why?
| | Gels | 2 | 2012 | 82 | 0.110 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2012 | 107 | 0.110 |
Why?
| | Down-Regulation | 2 | 2016 | 636 | 0.110 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2016 | 267 | 0.110 |
Why?
| | CD4 Lymphocyte Count | 2 | 2012 | 266 | 0.110 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2016 | 362 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 376 | 0.110 |
Why?
| | Receptors, Interleukin-1 | 1 | 2015 | 218 | 0.110 |
Why?
| | Colitis | 1 | 2016 | 242 | 0.110 |
Why?
| | Male | 11 | 2022 | 63674 | 0.110 |
Why?
| | Smoking | 1 | 2020 | 1501 | 0.100 |
Why?
| | HIV Envelope Protein gp120 | 2 | 2012 | 57 | 0.100 |
Why?
| | Macrophages | 2 | 2018 | 1480 | 0.100 |
Why?
| | HIV Antibodies | 1 | 2012 | 57 | 0.100 |
Why?
| | DNA-Binding Proteins | 4 | 2012 | 1443 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 185 | 0.100 |
Why?
| | Interleukin-1beta | 3 | 2021 | 372 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1928 | 0.090 |
Why?
| | Raltegravir Potassium | 1 | 2010 | 17 | 0.090 |
Why?
| | Middle Aged | 7 | 2020 | 31150 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 985 | 0.090 |
Why?
| | Placebos | 1 | 2011 | 201 | 0.090 |
Why?
| | Mice, Inbred BALB C | 4 | 2016 | 1245 | 0.090 |
Why?
| | Host-Pathogen Interactions | 3 | 2024 | 352 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2282 | 0.080 |
Why?
| | Hematopoiesis | 1 | 2011 | 183 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 265 | 0.080 |
Why?
| | Adult | 7 | 2020 | 35572 | 0.080 |
Why?
| | Lipopolysaccharides | 3 | 2019 | 875 | 0.080 |
Why?
| | Cell Lineage | 1 | 2011 | 333 | 0.080 |
Why?
| | Administration, Oral | 1 | 2010 | 786 | 0.070 |
Why?
| | Mice, Knockout | 4 | 2021 | 2871 | 0.070 |
Why?
| | RNA, Viral | 2 | 2011 | 619 | 0.070 |
Why?
| | Models, Genetic | 1 | 2011 | 594 | 0.070 |
Why?
| | Sindbis Virus | 1 | 2007 | 10 | 0.070 |
Why?
| | Anti-Retroviral Agents | 2 | 2024 | 231 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 381 | 0.070 |
Why?
| | Biomarkers | 2 | 2019 | 3973 | 0.070 |
Why?
| | Nucleic Acid Conformation | 1 | 2011 | 706 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2015 | 3381 | 0.070 |
Why?
| | Nanoparticles | 1 | 2011 | 374 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2007 | 138 | 0.070 |
Why?
| | Antigens, CD | 2 | 2020 | 489 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1367 | 0.060 |
Why?
| | Young Adult | 5 | 2020 | 12426 | 0.060 |
Why?
| | Sexual Behavior | 2 | 2020 | 483 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2022 | 720 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2011 | 712 | 0.060 |
Why?
| | Gene Expression Regulation | 3 | 2019 | 2548 | 0.060 |
Why?
| | Zimbabwe | 1 | 2024 | 54 | 0.060 |
Why?
| | Cohort Studies | 3 | 2019 | 5420 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2018 | 4083 | 0.050 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2022 | 29 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2019 | 5440 | 0.050 |
Why?
| | Bacteroides fragilis | 1 | 2022 | 13 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2022 | 135 | 0.050 |
Why?
| | Interleukin-12 | 1 | 2022 | 118 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 147 | 0.050 |
Why?
| | Immunologic Factors | 1 | 2022 | 231 | 0.040 |
Why?
| | Ribonuclease III | 2 | 2011 | 37 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 23 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 134 | 0.040 |
Why?
| | Bacteroides | 1 | 2019 | 19 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2019 | 2708 | 0.040 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 14 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 30 | 0.040 |
Why?
| | HLA-DQ beta-Chains | 1 | 2019 | 61 | 0.040 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 91 | 0.040 |
Why?
| | Spondylarthritis | 1 | 2019 | 45 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 87 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 226 | 0.040 |
Why?
| | Colon | 1 | 2020 | 254 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2019 | 324 | 0.040 |
Why?
| | Genetic Loci | 1 | 2019 | 275 | 0.030 |
Why?
| | Caspase 1 | 1 | 2018 | 143 | 0.030 |
Why?
| | Protein Transport | 1 | 2019 | 428 | 0.030 |
Why?
| | Base Sequence | 2 | 2012 | 2142 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1085 | 0.030 |
Why?
| | Oxazines | 1 | 2016 | 28 | 0.030 |
Why?
| | Virus Diseases | 1 | 2019 | 211 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2018 | 237 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 43 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1097 | 0.030 |
Why?
| | Adolescent | 3 | 2020 | 20391 | 0.030 |
Why?
| | Monocytes | 1 | 2019 | 551 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 582 | 0.030 |
Why?
| | Neuroglia | 1 | 2016 | 168 | 0.030 |
Why?
| | Retroviridae | 1 | 2015 | 99 | 0.030 |
Why?
| | Herpesviridae Infections | 1 | 2016 | 141 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2019 | 478 | 0.030 |
Why?
| | Pyridones | 1 | 2016 | 159 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 401 | 0.030 |
Why?
| | Immobilized Proteins | 1 | 2015 | 10 | 0.030 |
Why?
| | Neutralization Tests | 1 | 2015 | 73 | 0.030 |
Why?
| | Herpes Zoster | 1 | 2019 | 317 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 320 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 653 | 0.030 |
Why?
| | Aged | 3 | 2019 | 22099 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 331 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 177 | 0.030 |
Why?
| | Extracellular Space | 1 | 2015 | 120 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 307 | 0.030 |
Why?
| | Piperazines | 1 | 2016 | 342 | 0.030 |
Why?
| | Endotoxemia | 1 | 2015 | 86 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 412 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 274 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1839 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1040 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2015 | 811 | 0.030 |
Why?
| | Survivors | 1 | 2016 | 464 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 840 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2012 | 131 | 0.020 |
Why?
| | Administration, Topical | 1 | 2012 | 145 | 0.020 |
Why?
| | rev Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 6 | 0.020 |
Why?
| | Dendrimers | 1 | 2011 | 13 | 0.020 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 22 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1304 | 0.020 |
Why?
| | Fibroblasts | 1 | 2016 | 948 | 0.020 |
Why?
| | Peritoneum | 1 | 2011 | 41 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2011 | 88 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2011 | 82 | 0.020 |
Why?
| | Lymphoid Tissue | 1 | 2011 | 67 | 0.020 |
Why?
| | DEAD-box RNA Helicases | 1 | 2011 | 66 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2011 | 159 | 0.020 |
Why?
| | Viremia | 1 | 2011 | 131 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2011 | 122 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3076 | 0.020 |
Why?
| | Antibody Formation | 1 | 2011 | 290 | 0.020 |
Why?
| | HIV Envelope Protein gp160 | 1 | 2009 | 5 | 0.020 |
Why?
| | SELEX Aptamer Technique | 1 | 2009 | 14 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2011 | 333 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2073 | 0.020 |
Why?
| | Interferon Type I | 1 | 2009 | 139 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 3794 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 3717 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 5762 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 4925 | 0.020 |
Why?
| | Cricetinae | 1 | 2007 | 277 | 0.020 |
Why?
| | Molecular Weight | 1 | 2007 | 332 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2015 | 1902 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2007 | 179 | 0.020 |
Why?
| | Aedes | 1 | 2007 | 57 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7084 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1698 | 0.020 |
Why?
| | RNA Stability | 1 | 2007 | 102 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 9763 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 573 | 0.020 |
Why?
| | Infant | 1 | 2019 | 9025 | 0.010 |
Why?
| | Brain | 1 | 2016 | 2679 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2832 | 0.010 |
Why?
| | Child, Preschool | 1 | 2019 | 10518 | 0.010 |
Why?
| | Liver | 1 | 2011 | 1839 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2781 | 0.010 |
Why?
| | Proteins | 1 | 2007 | 942 | 0.010 |
Why?
| | Child | 1 | 2019 | 20882 | 0.010 |
Why?
|
|
Neff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|